Rivaroxaban reduces limb events after revascularization in patients with renal impairment

In a cohort of patients with renal impairment who underwent peripheral revascularization, rivaroxaban reduced the primary composite endpoint, driven by a marked reduction in limb events, according to data from the VOYAGER PAD trial.